epratuzumab
information and resources from the National Cancer Institute
NCI Thesaurus | epratuzumab
A recombinant, humanized monoclonal antibody directed against CD22, a cell surface glycoprotein present on mature B-cells and on many types of malignant B-cells. After binding to CD22, epratuzumab's predominant antitumor activity appears to be mediated through antibody-dependent cellular cytotoxicity (ADCC). NCI Thesaurus | epratuzumab
A recombinant, humanized monoclonal antibody directed against CD22, a cell surface glycoprotein present on mature B-cells and on many types of malignant B-cells. After binding to CD22, epratuzumab's predominant antitumor activity appears to be mediated through antibody-dependent cellular cytotoxicity (ADCC).
|
|
|
|
news articles
Immunomedics Reports Updated Clinical Results of Epratuzmab ... Dec 9, 2005
PR Newswire (press release), ...announced today results of a trial conducted at eight centers in Europe testing the safety and response rates of its lead product, epratuzumab, in combination ...
Immunomedics Announces Outcome of 2005 Annual Meeting of ... Dec 7, 2005
PR Newswire (press release), ...year was one of significant accomplishments for Immunomedics, demonstrated by the fact that we received Fast Track designation by FDA for epratuzumab in the ...
Immunomedics Reports Preclinical Results on New Therapeutic Dec 15, 2005
Yahoo! News (press release) Our lead product candidate, epratuzumab, is currently in two pivotal Phase III trials for the treatment of patients with moderate and severe lupus (ALLEVIATE A ...
Other News To Note Dec 9, 2005
TMCnet Immunomedics Inc., of Morris Plains, NJ, said results of a European trial of epratuzumab in combination with rituximab to treat patients with non-Hodgkin's ...
Immunomedics Reports Humanized Anti-CD20 Antibody Appears Safe and ... Dec 12, 2005
PR Newswire (press release), It contains over 90% of human amino acid sequences and the human framework regions are identical to epratuzumab, the Company's CD22 humanized antibody that has ...
Immunomedics Describes Alleviate Trials Design Nov 28, 2005
PR Newswire (press release), ...and comments on the Company's product portfolio, Mr. Gorman will provide details with regard to the Phase III ALLEVIATE trials, evaluating epratuzumab as a ...
Immunomedics Reports Updated Clinical Results of Epratuzmab ... Dec 9, 2005
PR Newswire (press release), ...announced today results of a trial conducted at eight centers in Europe testing the safety and response rates of its lead product, epratuzumab, in combination ...
Immunomedics Announces Outcome of 2005 Annual Meeting of ... Dec 7, 2005
PR Newswire (press release), ...year was one of significant accomplishments for Immunomedics, demonstrated by the fact that we received Fast Track designation by FDA for epratuzumab in the ...
Immunomedics Reports Preclinical Results on New Therapeutic Dec 15, 2005
Yahoo! News (press release) Our lead product candidate, epratuzumab, is currently in two pivotal Phase III trials for the treatment of patients with moderate and severe lupus (ALLEVIATE A ...
Other News To Note Dec 9, 2005
TMCnet Immunomedics Inc., of Morris Plains, NJ, said results of a European trial of epratuzumab in combination with rituximab to treat patients with non-Hodgkin's ...
Immunomedics Reports Humanized Anti-CD20 Antibody Appears Safe and ... Dec 12, 2005
PR Newswire (press release), It contains over 90% of human amino acid sequences and the human framework regions are identical to epratuzumab, the Company's CD22 humanized antibody that has ...
Immunomedics Describes Alleviate Trials Design Nov 28, 2005
PR Newswire (press release), ...and comments on the Company's product portfolio, Mr. Gorman will provide details with regard to the Phase III ALLEVIATE trials, evaluating epratuzumab as a ...
|
|
